Kaleido Biosciences Revenue and Competitors

Boston, MA USA

Location

$230.9M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Kaleido Biosciences's estimated annual revenue is currently $855k per year.(i)
  • Kaleido Biosciences received $101.0M in venture funding in June 2018.
  • Kaleido Biosciences's estimated revenue per employee is $57,000
  • Kaleido Biosciences's total funding is $230.9M.
  • Kaleido Biosciences's current valuation is $94.1M. (January 2022)

Employee Data

  • Kaleido Biosciences has 15 Employees.(i)
  • Kaleido Biosciences grew their employee count by -75% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.3M6811%$3MN/A
#2
$1.4M7N/AN/AN/A
#3
$15.7M78-26%$176.6MN/A
#4
$39060M679084%$30 b$234.4B
#5
$130.9M651N/AN/AN/A
#6
$25.7M161N/AN/AN/A
#7
$124.8M9101%$567.2M$2.2B
#8
$1.2M14N/AN/AN/A
#9
$0.9M6N/AN/AN/A
#10
$2360M410111%$22.5M$10.7B
#11
$12.2M79N/AN/AN/A
#12
$275.4M112613%N/A$4.4B
#13
$11.2M7231%N/AN/A
#14
$14.8M67-24%N/AN/A
#15
$0.1M4N/AN/AN/A
#16
$2.7M27N/AN/AN/A
#17
$87.4M564N/AN/AN/A
#18
$46.5M2332%$396M$424.9M
#19
$8.4M54N/AN/AN/A
#20
$0.5M9N/AN/AN/A
Add Company

Kaleido is a clinical-stage healthcare company leading the discovery and development of novel chemistries to drive functions of the microbiome organ to treat disease and improve human health. The company is advancing a robust pipeline of Microbiome Metabolic Therapies (MMTs) across a range of therapeutic areas, including rare genetic disorders. Kaleido's unique discovery and development model is redefining traditional R&D, enabling product candidates to advance rapidly into the clinic, dramatically reducing time and cost. Learn more at https://kaleido.com/.

keywords:N/A

$230.9M

Total Funding

15

Number of Employees

$855k

Revenue (est)

-75%

Employee Growth %

$94.1M

Valuation

N/A

Accelerator

Kaleido Biosciences News

2022-04-13 - Kaleido Biosciences is winding up operations as bluebird bio ...

Microbiome-focused company, Kaleido Biosciences, in a filing with the US Securities and Exchange Commission (SEC) on Friday, announced its...

2022-04-06 - Flagship's Kaleido Biosciences shuts down, as more biotechs ...

A few months after Flagship Pioneering spinout Kaleido Biosciences slashed 30 percent of its workforce, the company said it is shutting down...

2022-04-06 - Microbiome biotech Kaleido Biosciences shutters amid cash ...

Kaleido was formed in 2015 by Flagship Pioneering, a venture capital firm whose other microbiome portfolio companies include Seres Therapeutics...

2021-08-09 - Kaleido Biosciences : Announces New Chairperson Appointment to its Board of Directors

LEXINGTON, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced the appointment of current Boa ...

2021-04-21 - KALEIDO BIOSCIENCES, INC. Kaleido Biosciences : Announces Collaboration with Robert Jenq, M.D., to Explore Potential of its Microbiome Metabolic Therapies (MMT) in Preventing Febrile Neutropenia

LEXINGTON, Mass. - Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a small molecule driven approach to targeting the microbiome to treat disease and improve human health, today announced a research collaboration with researcher Robert Jenq, M.D. Professor of ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.4M1515%N/A
#2
$1.3M1536%N/A
#3
$2.6M15-42%N/A
#4
$1.4M16-11%N/A
#5
$1.4M16N/AN/A

Kaleido Biosciences Funding

DateAmountRoundLead InvestorsReference
2017-09-19$UndisclosedUndisclosedFlagship PioneeringArticle
2018-06-26$101.0MCFidelityArticle